

P.O.Box 377 Tanke Svilandsgate 30, Stavanger 4002, Norway

Tel: +47 51 51 16 30

Email: <u>mari.kaada@laerdal.com</u>

November 7, 2022

Federal Communications Commission 445 12<sup>th</sup> Street SW Washington, DC 20554

Subject: Limited Agency Agreement

Laerdal Medical AS FCC ID: QHQ-LA

To Whom It May Concern:

We, *Laerdal Medical AS*, hereby authorized Intertek Testing Services to act as our Agent for the purpose of preparing application for FCC ID number *QHQ-LA* under all applicable parts of the FCC rules and regulations.

The effective date of this limited agency agreement is *November 7, 2022*. The Limited Agency Agreement expires on *December 31, 2022*, unless sooner terminated or extended by written notice to Intertek Testing Services and the Federal Communications Commission.

This is to advise that we are in full compliance with the Anti-Drug Abuse Act. The applicant is not subject to a denial of federal benefits pursuant to Section 5301 of the Anti-Drug Act of 1988, 21 U.S.C. 862, and no party to the application is subject to a denial of federal benefits pursuant to that section.

If you have any questions or comments, please do not hesitate to contact me.

Sincerely,

Mari Kaada

Mari Kaada Corporate Director QA/RA Norway, Stavanger Laerdal Medical AS